Miura Global Management LLC cut its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 66.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 5,000 shares of the biotechnology company's stock after selling 10,000 shares during the period. Repligen comprises about 0.9% of Miura Global Management LLC's holdings, making the stock its 20th biggest holding. Miura Global Management LLC's holdings in Repligen were worth $744,000 as of its most recent filing with the SEC.
A number of other hedge funds have also modified their holdings of RGEN. Andra AP fonden purchased a new stake in shares of Repligen in the second quarter valued at about $25,000. International Assets Investment Management LLC acquired a new stake in Repligen in the second quarter valued at approximately $33,000. UMB Bank n.a. raised its holdings in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 130 shares in the last quarter. Blue Trust Inc. raised its holdings in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 127 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in Repligen in the third quarter valued at approximately $45,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company's stock.
Analyst Ratings Changes
A number of analysts have weighed in on RGEN shares. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, November 22nd. Royal Bank of Canada reissued an "outperform" rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They set a "peer perform" rating on the stock. Finally, Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $190.25.
Read Our Latest Analysis on Repligen
Repligen Stock Up 0.5 %
Shares of RGEN stock traded up $0.70 during mid-day trading on Wednesday, reaching $149.20. 229,863 shares of the company were exchanged, compared to its average volume of 661,844. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market capitalization of $8.36 billion, a P/E ratio of -401.34, a P/E/G ratio of 4.53 and a beta of 0.96. The business's 50 day simple moving average is $141.29 and its 200 day simple moving average is $142.10.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the business posted $0.23 earnings per share. Research analysts predict that Repligen Co. will post 1.52 earnings per share for the current year.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
